Business
Trading Update
ProBiotix Health plc reported a strong trading performance for the year ended 31 December 2025, with sales increasing by 45% to £2.72 million and gross profit rising by 46% to £1.46 million, leading to a gross profit margin of 54%. The company significantly reduced its EBITDA loss from continuing operations by 31% to £445,000, while maintaining a healthy cash balance of £1.27 million. The first quarter of 2026 shows considerable promise with an order book up 110% to £1.3 million, driven by new customer acquisition and expansion into new markets, including a new menopause-focused product line and entry into Korea. Disclaimer*
About this update from Probiotix Health Plc
[{"type":"text","content":"\n\n21 January 2026\n \nProBiotix Health plc\n(\"ProBiotix\" or the \"Company\" or, together with its subsidiary, the \"Group\")\n \nTrading Update\n \nProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce a trading update for the financial year ended 31 December 2025.\n \nKey highlights*:\n \n· Sales +45% to £2.72m (2024: £1.88m)\n· Gross profit +46% to £1.46m (2024: £997,000) \n· EBITDA loss from continuing operations down 31% to £445,000 (2024: £642,000)**\n· Gross Profit margin increased to 54% (2024: 53%)\n· Strong cash balance of £1.27m at year-end\n · Record Q1 2026 order book +110% at £1.3m\n \n* Figures are subject to audit\n** Before share based payment expense\n \nReview of the year\n \nWe are delighted to report that 2025 was a year of continued and satisfactory progress for ProBiotix, delivered against our stated strategy and operational objectives. The strong trading performance reflects growing commercial traction across our core markets, supported by both new customer acquisition, and continued positive growth from already established customer partnerships. Alongside the commercial momentum, we implemented a number of internal initiatives to enhance operational scalability,...